drugset / Trial / NCT00907764

Stress Echocardiography Study With Regadenoson

NCT00907764

Phase 2 Terminated 22 enrolled Gilead Sciences
Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

Regadenoson is approved in the US under the brand name Lexiscan for myocardial perfusion imaging. This study will test whether regadenoson is an appropriate stress agent for stress echocardiography.

Timeline

Start
2009-04
Primary completion
2010-04
Completion
2010-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Regadenoson Diagnostic / imaging agent 400 ug